A highly promising biomarker for prediction of future inflammatory activity (attacks or new lesions on MRI) at the time of the ICDE is intrathecal production of the chemokine CXCL13, as shown recently in a study of 41 patients with ICDE and 26 patients with other forms of MS (49). Here, CXCL13 is linked to myeloid sarcoma.